Strong buy after MA 200 has come with insane violence. After a pull back of few days we have seen the start of a new uptrend. First TP is around 26,7 dollars where the gap down has left its trail.
Will Women get an F&DA approval for their VIAGRA?? Good entry with LT target 4-5 if approved. This chart is for own use. Viewers come to own conclusions and appreciate comments and learning thoughts.
As showed in the chart $BHC comes from a long bullish flag. Price is reaching the buy zone where the major bullish trendline goes through. It's not yet a buy but we are approching such zone. Strategy: watch and wait.
BLRX BL-8040 Overview BL-8040 is a novel, short peptide that functions as a high-affinity antagonist for CXCR4, which BioLineRx is developing for the treatment of solid tumors, acute myeloid leukemia, or AML, and stem-cell mobilization for bone-marrow transplantation. Solid Tumors: In January 2016, BioLineRx entered into a collaboration with MSD, known as ...
$Teva is still positive in the uptrend although the candle of yesterday has turned some indicators in bearish position. Over the mid term bullish trend is still strong. Having said that next candles have to be monitored because on a monthly basis there is a potential dragon fly bearish, thus a prompt recover toward the upper edge of the bullish flag is important...
I am waiting for an entry long in $BHC but positive signs are already there especially RSI is giving an insight, MA 200 is almost close and it might be probable a new test. Monthly RSI is down and on a weekly basis price is approcing the pullback of the third bullish wave. For the time being, given the positive earnings release a bullish trend continuation is...
ENDP Endo International plc is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced...
$MYL: Bullish wedge is about to be completed as yesterday we have seen rising bullish pressure, actually price wasn't able to break out the upper edge and we have seen a sharp intraday pullback (about 3%). Today buyers are coming in, thus price is heading upper edge. Volumes are rising, MACD on a weekly basis turn positive. Test of mid and long term support as...
Pharmaceutical stocks represents a defensive asset when a positive market cycle is about to finish or when it is foreseen a cycle less positive than the previous one. In such context pharma stocks should have an advantage because of inelastic demand for such goods. Novartis ($NVS,$NOVN) is one of the candidate to break up as the price is moving in a triangle...
$MYL after the earnings release has lost ground: investors actually pushed back the price yesterday with a massive bearish candle over -6%. Although the picture for generics look less positive than expected in the years to come, we should consider that demand for such goods is always "on" and today's prices (for these companies) are keeping such trend embodied....
Vertex has consolidating the price in a bullish wedge. A key resistence zone is at 178.57, a break out of such edge is interesting because it might pull up the price toward new high records. Stock is under the radar
Celgene helped by the company's buyback has turned positive after a complicated year. Despite this in terms of foundamentals two drugs are on the way to be developped but such developments will be revealed in the next year so patient is a must for those who wants to invest of something concreate. On a technical point of view yesterday price faild to cross MA 200....
Kempharm is looking at a possible resurgence in stock prices... The most recent news from the pharmaceutical company is positive, with a successful test of an ADHD prodrug. The current price looks like it is close to a fibbonaci level. If it breaks the downline and trends up, it would be a recovery from a strong downtrend, but the historical prices of this stock...
($ALXN) I have already flagged up alexion when price was around 112-115 dollars saying there was a good opportunity for an entry long. Recently we have had an important sign because the price broke the hystorical downtrend since july 2015. We had some indicators overbought but thank to this pullback we can wait for a second entry long position. A suitable...
Weekly chart: we have the downtrend channel clearly defined on a weekly basis. On a monthly basis we have already had a minimum of swing with a dragon fly bullish, on a daily chart some signs of an incoming uptrend as described in the latest posts...but tomorrow...tomorrow is where we play the game with the last resistence in place at 86.72 dollars. Once we get...
($TEVA) was accelerating the uptrend but since some days it has come back on its path inside a bullish flag. It is important to note that next week earnings will be released so high volatility should be expected. Masch is about to turn on bullish mode RSI is quite down and vortex is neutral. I might expect that some investors will get long before the earnings...
I will not go into details on this one. Bottom line is, I am impressed with Otsuka's vision and its recent developments - and many other things which I will not explain here. I will be entering a long position soon, watching the action at these levels. This is will be one of the stocks I would recommend to add to your stocks portfolio. -Keep it Real-
Time to raise up the head has come for ALexion pharmaceuticals. After some years in a trading range and a never ending downtrend since 2015 (black line) price has broken it up reaching recently 135.87 dollars. As showned in the graph we have an important technical signal which is the cross between MA 50 and MA 200. We have also the RSI confirming tghe momentum and...